Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cyclobenzaprine Clear all
Recruiting Phase 2 Interventional

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

NCT07621237
View directory record Official record
Conditions
Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
Interventions
TNX-102 SL, Placebo sublingual tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
27
States / cities
Phoenix, Arizona • Buena Park, California • Chino, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Trigger Point Injection for Myofascial Pain Syndrome in the Low Back: A Randomized Controlled Trial

NCT04704297
View directory record Official record
Conditions
Low Back Pain, Myofascial Pain Syndrome Lower Back
Interventions
Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below., Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below., Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
Drug
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional Results available

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

NCT03110575
View directory record Official record
Conditions
PTSD
Interventions
TNX-102 SL
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
32
States / cities
Phoenix, Arizona • Rogers, Arkansas • Beverly Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis

NCT02651324
View directory record Official record
Conditions
Idiopathic Scoliosis, Post-operative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

NCT03841773
View directory record Official record
Conditions
PTSD
Interventions
TNX-102 SL, Placebo SL Tablets
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 25, 2026, 4:59 PM EDT
Not yet recruiting Phase 4 Interventional

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

NCT07664956
View directory record Official record
Conditions
Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified, Adenomyosis of Uterus, Fibroid Uterus, Chronic Pelvic Pain, Endometriosis, Menorrhagia, Endometritis, Adnexal Diseases
Interventions
Cyclobenzaprine
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Driving Simulation to Assess Non-Sedative Effects of Tolperisone

NCT03353922
View directory record Official record
Conditions
Driving Impaired
Interventions
Cyclobenzaprine 10 Mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Neurana Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Long Beach, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

NCT01903265
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
TNX-102 SL 2.8mg, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

NCT04508621
View directory record Official record
Conditions
Fibromyalgia
Interventions
TNX-102 SL, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

NCT02015234
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
TNX-102 SL
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
13
States / cities
Denver, Colorado • Brooksville, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial

NCT00790270
View directory record Official record
Conditions
Cervical Strain
Interventions
Cyclobenzaprine, Ibuprofen, Ibuprofen plus Cyclobenzaprine
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia

NCT02436096
View directory record Official record
Conditions
Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases
Interventions
TNX-102 SL Tablet, 2.8mg, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 25, 2026, 4:59 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

NCT01151787
View directory record Official record
Conditions
Chronic Migraine
Interventions
cyclobenzaprine hydrochloride, placebo
Drug
Lead sponsor
Kennedy Medical Group
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cherry Hill, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 25, 2026, 4:59 PM EDT